Table 1.

Quality of Life (QoL) and Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapy: Eculizumab and Ravulizumab

Drug	Study Name	Number of Participants	Main Message	Ref
Eculizumab	Triumph	87 (43 eculizumab)	FACIT-F score significantly increased from baseline in eculizumab arm	[16, 51]
	Shepherd	97	Both FACIT-F score and EORTC-QLQ-C30 improved from baseline to week 52	[14, 51]
	Japanese experience	54	Both FACIT-F score and EORTC-QLQ-C30 meaningfully increased	[52]
Ravulizumab	301	246 (125 ravulizumab, 121 eculizumab)	Improvement in FACIT-F score and EORTC-QLQ-C30 similar in the ravulizumab and eculizumab group	[33]
	302	195 (97 ravulizumab, 98 eculizumab)	Change in FACIT-F score from the baseline significantly higher in the ravulizumab group; change in EORTC-QLQ-C30 similar in both groups	[29]
	302 extension	191 (96 ravulizumab, 95 eculizumab to ravulizumab)	Mean FACIT-F score remained stable through study period; mean EORTC-QLQ-C30 was similar in both groups	[53]
	302s	95	Ravulizumab preferred over eculizumab by a significant proportion of patients	[54]

Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer-QLQ-C30 score; FACIT-F, the Functional assessment of chronic illness-Fatigue.